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Abstract
Background: Aspirin and eugenol were esterified to synthesize aspirin eugenol ester (AEE). As a pale yellow and
odourless crystal, AEE reduced the gastrointestinal damage of aspirin and vulnerability of eugenol. The study was
conducted to evaluate the preventive effects of AEE on blood lipids in rats with high fat diet (HFD).
Methods: Suspensions of AEE and simvastatin were prepared in 5% carboxymethyl cellulose sodium (CMC-Na). In
order to observe the intervention effects, the drugs and HFD were administrated at the same time. Based on
individual weekly body weight (BW), AEE was intragastrically administrated at the dosage of 18, 36 and 54 mg/kg.
Simvastatin (10 mg/kg) and CMC-Na (20 mg/kg) were used as control drug. After 6 weeks of administration, the
changes of BW and blood lipid indices including triglyceride (TG), low density lipoprotein (LDL), high density
lipoprotein (HDL) and total cholesterol (TCH) were determined in the experiment.
Results: The rat blood lipids profile in model group was remarkably different after feeding 6-weeks HFD. TG, TCH
and LDL indexes in model group were increased significantly compared with those in control group (p < 0.01). AEE
at the dosage of 54 mg/kg significantly decreased levels of TG, TCH and LDL (p < 0.01), and slowed the rate of BW
gain in comparison with model group (p < 0.05). Moreover, high dose AEE showed better effects than simvastatin
on reducing TCH level and similar effects on TG, HDL and LDL.
Conclusion: AEE could remarkably reduce levels of TG, TCH and LDL in rats with high fat diet, and slow the rate of
body weight gain. It was conducted that AEE was a potential candidate on reducing blood lipids level. The
mechanism of action of AEE should be investigated in further studies.
Keywords: Aspirin eugenol ester (AEE), Blood lipids, Body weight, High fat diet, Rats
Background
Hyperlipidemia is a heterogeneous group of disorders
characterized by an excess of lipids in blood stream such
as the increased serum levels of triglycerides (TG), total
cholesterol (TCH), low-density lipoprotein (LDL) as well
as decreased levels of high-density lipoprotein (HDL) [1, 2].
Hyperlipidemia, as the major risk factor for the develop-
ment of cardiovascular diseases, is becoming a major health
problem in the world [3].
Aspirin could ameliorate hyperlipidemia induced by
high fat diet and hyperinsulinemia in rats [4]. Moreover,
aspirin could diminish hypertriglyceridemia in obese
rodents and has potential in hyperlipidemia prevention
[5]. Eugenol as volatile oil is extracted from dry alabas-
trum of Eugenia caryophyllata. Therapeutic effects of
eugenol on hyperlipidemia had been proved in previous
study [6, 7]. Four-week administration of eugenol could
significantly decrease the serum lipid profile in normal
albino rabbits [8].
Based on prodrug principle and therapeutic effects of
aspirin and eugenol on hyperlipidemia, aspirin eugenol
ester (AEE) as a new drug was synthesized [9]. The me-
tabolites of AEE had been confirmed in beagle dog and
liver microsomes. AEE could be metabolized into aspirin
and eugenol in vitro and in vivo, which could show their
original activities and act synergistically [10]. AEE also
reduced the side effects of its precursor such as the
gastrointestinal damage of aspirin and irritation of eu-
genol [11]. The acute toxicity of AEE was less than its
* Correspondence: yangyue10224@163.com; lijy1971@163.com
†Equal contributors
Key Lab of New Animal Drug Project of Gansu Province, Key Lab of
Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou
Institute of Husbandry and Pharmaceutical Science of CAAS, No.335,
jiangouyan, qilihe district, Lanzhou 730050, China
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Karam et al. Lipids in Health and Disease  (2016) 15:196 
DOI 10.1186/s12944-016-0369-2
precursor, which was 0.02 times of aspirin and 0.27
times of eugenol [9, 11]. The teratogenicity and mutage-
nicity of AEE have been investigated. AEE did not show
any mutagenesis in Ames test and the mouse bone mar-
row micronucleus assay [11, 12]. Moreover, the effects of
AEE had been evaluated in animal model. The results
showed that AEE had positive effects on antithrombosis,
anti-inflammatory, analgesia and antipyretic [9, 11, 13].
Therapeutic strategies for hyperlipidemia treatment
depend on reducing blood lipids. There are many chem-
ical drugs that lower cholesterol level in the body such
as statins, fibrates, ezetimibe and nicotinic acid. How-
ever, most of them are expensive and have undesirable
effects [14]. There is an obvious need for more effica-
cious and alternative treatment options for hyperlipid-
emia. In our previous study, AEE (50 mg/kg and
160 mg/kg) could reduce TCH and TG in rats with
standard diet [11]. Moreover, five-week administration
of AEE (54 mg/kg) could normalize blood lipids profile
in hyperlipidemic rats [15]. So there are increasing inter-
est to evaluate the intervention effects of AEE on blood
lipids in rat with high fat diet. This study will increase




Aspirin eugenol ester (AEE), transparent crystal with the
purity of 99.5% by RE-HPLC, was prepared in Key Lab
of New Animal Drug Project of Gansu Province, Key
Lab of Veterinary Pharmaceutical Development of Agri-
cultural Ministry, Lanzhou Institute of Husbandry and
Pharmaceutical Sciences of CAAS. CMC-Na and simva-
statin was supplied by Tianjin Chemical Reagent Com-
pany (Tianjin, China). Standard compressed rat feed and
high diet food were supplied by Keao Xieli Co., Ltd
(Beijing, China). Standard rat diet consisted of 12.3%
lipids, 63.3% carbohydrates, and 24.4% proteins (kcal)
and high fat diet (standard rat diet 77.8%, yolk power
10%, lard 10%, cholesterol 2%, bile salts 0.2%) consisted
of 41.5% lipids, 40.2% carbohydrates, and 18.3% proteins
(kcal). The TG, TCH, LDL and HDL kits were provided
by Ningbo Medical System Biotechnology Co., Ltd
(Ningbo, China). Erba XL-640 analyzer (German) was
used to measure the blood lipid indices.
Animals
Seventy Sprague–Dawley (SD) male rats were purchased
from the animal breeding facilities of Gansu University
of Chinese Medicine (Lanzhou, China). The rats were
housed in plastic cages of appropriate size (50 × 35 ×
20 cm, ten rats per cage) with stainless steel wire cover
and chopped bedding. Rat feed and drinking water were
supplied ad libitum. Light/dark regime was 12/12 h and
living temperature was 22 ± 2 °C with relative humidity
of 55 ± 10%. Animals were acclimatized for 2 weeks
before study initiation.
Serum sampling
At the end of the experiment, rats were fasted for 10–12
h and then anaesthetized with 1% pentobarbital sodium.
The blood samples were collected from the heart with
vacuum tube. The sera were obtained by centrifuging for
15 mins at the speed of 4000 g at 4 °C. Serum samples
were stored at −80 °C until the day of analysis.
Drug preparation
AEE and simvastatin liquid suspensions were prepared
in 0.5% of CMC-Na.
Study design
Rats were randomly divided into seven groups including
control, model, CMC-Na, simvastatin and three AEE
groups. The detailed design of the experiment is shown
in Table 1. Simvastatin was used as a positive control
(10 mg/kg). The administrations of food and drugs were
started at the same time. The volumes of CMC-Na and
drug suspensions were nearly equal. After 6-weeks ad-
ministration, the blood lipid levels were analyzed.
Statistics
The statistical analyses were carried out using IBM SPSS
19.0 (USA). All data obtained from the experiment are
expressed as mean ± standard deviation (SD). Statistical
differences were evaluated by using one-way ANOVA
with Tukey’s multiple comparison tests. P-values less
than 0.05 were considered statistically significant.
Table 1 Study design of the experiment
Groups Food Drug Dosage Concentration
Control SRD – – –
Model HFD – – –
CMC-Na HFD CMC-Na 20 mg/kg 5 mg/mL
Statin HFD Simvastatin 10 mg/kg 2.5 mg/mL
AEE Low HFD AEE 18 mg/kg 4.5 mg/mL
AEE Mid HFD AEE 36 mg/kg 9 mg/mL
AEE High HFD AEE 54 mg/kg 13.5 mg/mL
Rats were divided into seven groups. Control group was received SRD and the
rest groups were received HFD, respectively. Based on the individual weekly
body weight, rats were given with different drug suspension volume. CMC-Na
as a vehicle was used in control group. Simvastatin was designed as positive
drug. Different dose of three levels of AEE were administrated in the study.
The administration period was 6 weeks and then blood lipids were analyzed
AEE aspirin eugenol ester, SRD standard rat diet, HFD high fat diet
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Results
Intervention effects of AEE
After feeding rats with HFD for 6 weeks, the blood lipid
profile was notably different among the groups. There
were significant differences between control and model
groups (Table 2). In model group, TG, TCH and LDL
were increased significantly in comparison with the con-
trol group (p < 0.01). However, no change was observed
in HDL between control and model groups. There was
no significant difference between CMC-Na and model
groups. In comparing with model group, low and inter-
mediate dose of AEE had no effect on blood lipid in-
dexes except TCH index in AEE low group (p < 0.05).
AEE high dose significantly decreased TG, TCH and
LDL compared to model group (p < 0.01). AEE in differ-
ent dosages had no influence on HDL. Simvastatin as a
positive drug control could significantly decrease TCH
and LDL (p < 0.01). With regard to TG and HDL, no
changes were observed between simvastatin and model
groups.
The three groups were used to compare with control
and statin groups (Fig. 1). When compared with control
group, TG, TCH and LDL in AEE groups were signifi-
cant increased (p < 0.01 or p < 0.05). Notably, the mean
values of TG, TCH and LDL in AEE high group were
less than the values in low and intermediate AEE groups.
Simvastatin and AEE made similar effects on TG, HDL
and LDL indexes. However, simvastatin showed more
positive effects on TCH than AEE L and AEE M but not
AEE H (p < 0.01 or p < 0.05 Fig. 1d). In order to find out
the relationship between drug effects and the dosage,
intermediate and high AEE groups were compared with
low dose AEE group. The results showed that there was
only significant difference on TCH index in AEE high
group (p < 0.01 Fig. 1d). Interestingly, the mean values of
TG and LDL in AEE high group were the smallest in all
AEE groups.
Body weight
The body weights of all groups were recorded at the be-
ginning and ending of the experiment (Table 3). At the
beginning of the experiment, there was no significant
difference between all groups. At week 6, the body
weights in the group supplemented with AEE high dose
were significantly lower than those in model group (p <
0.05). The results showed that high dose of AEE could
reduce the rate of body weight gain. The body weights
in AEE intermediate and high groups were remarkably
lower than control group (p < 0.05 or p < 0.01). No dif-
ference was observed among statin and AEE groups.
The gains in body weights in AEE high group were sig-
nificantly lower than those in AEE low group (p < 0.05).
Discussion
Based on prodrug principle, aspirin and eugenol, as
starting precursors, were esterified to synthesize aspirin
eugenol ester (AEE). The positive effects of AEE on the
symptoms of inflammation, fever, pain and thrombosis
had been confirmed in animal disease model [9, 11, 13].
The blood chemistry results in 15-day oral dose toxicity
study showed AEE could significantly reduce the values
of TG and TCH both in male and female rat, which in-
dicated that this compound was potential for curing
hyperlipidemia [11]. In subsequent experiment, the regu-
lation effects of AEE on blood lipid profile in hyperlipid-
emic rats had been confirmed [15]. Based on this fact, it
is essential to evaluate the intervention effects of AEE
on blood lipids in rats with high fat diet fed.
The intervention effect of AEE was evaluated by com-
paring AEE groups with model group. AEE low and
intermediate dose showed no significant effect on blood
lipid indices except reducing TCH at AEE low dose. It is
noteworthy that high dose of AEE was highly effective in
reducing blood lipid indices such as TG and TCH. These
meant that the activity of AEE at high dose was better
than low and intermediate doses. So there was a positive
relationship between drug efficacy and dosage. Under
the present experimental conditions, the optimal dose
was considered to be 54 mg/kg for normalizing blood
lipid profile in high fat diet fed rat.
HDL is responsible for the transportation of choles-
terol to liver, which is essential for cholesterol removal
[16]. HDL levels of rat fed with high fat diet for six
weeks showed no changes in this study. There are sev-
eral possible reasons for this result. First of all, HFD
compositions such as the lack of saturated fat may be
insufficient to make substantial change on HDL. Second,
the constant values of HDL may be attributable to the
Table 2 The blood lipids levels after drugs administration for six weeks (n = 10)
Variables Control Model CMC-Na Statin AEE Low AEE Mid AEE High
TG (mmol/L) 0.53 ± 0.12** 0.89 ± 0.07 0.79 ± 0.19 0.83 ± 0.05 0.79 ± 0.23 0.77 ± 0.10 0.71 ± 0.07**
HDL (mmol/L) 0.72 ± 0.04 0.74 ± 0.08 0.69 ± 0.09 0.66 ± 0.13 0.73 ± 0.09 0.79 ± 0.10 0.65 ± 0.15
LDL (mmol/L) 0.25 ± 0.02** 0.50 ± 0.09 0.46 ± 0.06 0.39 ± 0.13** 0.45 ± 0.05 0.46 ± 0.10 0.36 ± 0.08**
TCH (mmol/L) 1.4 ± 0.10** 2.29 ± 0.26 2.13 ± 0.22 1.80 ± 0.16** 2.10 ± 0.22* 2.15 ± 0.15 1.66 ± 0.15**
*P < 0.05, **P < 0.01 significant difference compared to model group. TG triglyceride, HDL high density lipoprotein, LDL low density lipoprotein, TCH total
cholesterol. Blood lipids indices were increased in model group. The blood lipid levels were reduced in simvastatin and high dose AEE groups in varying degrees
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short duration of the experiment (only 6 weeks). Finally,
animal model used in the experiment may be a potential
cause. Literature indicated that most cholesterol in rat
blood circulation existed in HDL and this contributed to
reducing susceptibility of HDL level to HFD [17, 18].
HFD is a commonly used material to induce animal
disease such as hyperlipidemia, diabetes, obesity and ar-
teriosclerosis [19, 20]. In this experiment, the results of
body weight were not consistent with those in our previ-
ous study. There was no difference in body weight be-
tween control and model group. However, HFD with
same components significantly increased body weight at
the end of eighth week in Wistar rat [15]. The shortage
of HFD consumption time may be the reason for the re-
sults of no significant difference in body weight. Metab-
olism and liver function could be substantially changed
with HFD feeding [21]. It was necessary to give the rat
time to adjust for HFD gradually, which may slow the
rate of the body weight gain in certain period. It was
found that AEE dosage had different influence on body
weight. AEE high and middle dose made an impact on
body weight and there was significant difference between
low and high AEE groups. The results of AEE on body
weight were also the reason why 54 mg/kg was sug-
gested for optimal dosage.
Simvastatin is an inhibiter of 3-hydroxy-3-methylgluta-
ryl coenzyme A (HMG-CoA) which plays a crucial role
in cholesterol synthesis in liver cells. Simvastatin was
used as a positive drug control in this study and it de-
creased the levels of TCH and LDL. The effects of
10 mg/kg simvastatin on TCH and LDL were similar
with 54 mg/kg AEE. However, simvastatin had no influ-
ence in TG index and showed significant difference from
high dose AEE. From these results, it could be concluded
that AEE was more effective than simvastatin on redu-
cing blood lipid level. CMC-Na was widely used as a reli-
able drug vehicle in pharmaceutical industry [22, 23].
The effect of CMC-Na on blood lipid indexes was
eliminated by administrating equal volume CMC-Na to
Fig. 1 Comparative effects of AEE and simvastatin on blood lipid indexes (n = 10). aP < 0.05, aaP < 0.01 significant difference compared to control
group; bP < 0.05, bbP < 0.01 significant difference compared to statin group; cP < 0.05, ccP < 0.01 significant difference compared to AEE L. CMC-Na:
carboxymethylcellulose sodium, AEE L: low dose of AEE (18 mg/kg), AEE M: intermediate dose of AEE (36 mg/kg), AEE H: high dose of
AEE (54 mg/kg). a, b, c and d were TG, HDL, LDL and TCH, respectively
Table 3 Body weights of rats at the beginning and the end of
the experiment (n = 10)
Groups Week 1 Week 6
Control 209 ± 15 385 ± 20
Model 216 ± 11 368 ± 25
CMC-Na 209 ± 10 365 ± 20
Statin 220 ± 22 355 ± 20a
AEE Low 220 ± 17 366 ± 31
AEE Mid 211 ± 15 356 ± 20a
AEE High 213 ± 14 340 ± 15*aab
*P < 0.05 significant difference compared to model group; aP < 0.05, aaP < 0.01
significant difference compared to control group; bP < 0.05 significant
difference compared to AEE low group; Week 1: beginning of the experiment;
Week 6: the end of the experiment
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control group. Therefore, it manifested that the effects
of AEE was not related to CMC-Na.
Therefore, intragastrical administration of AEE had a
significant intervention effects in HFD fed rat. AEE was
decomposed into salicylic acid and eugenol after absorp-
tion. The effects of AEE on reducing blood lipid indexes
may be mainly from synergetic action of aspirin and eu-
genol. More studies are necessary to investigate the
action mechanism of AEE such as evaluation of inhibitory
effect on digestive enzymes and influence on metabolic
targets.
Conclusions
Under the present study condition, AEE at daily dosage
of 54 mg/kg BW for six weeks could remarkably reduce
levels of TG, TCH and LDL in rats with high fat diet,
and slow the rate of body weight gain. Moreover, AEE at
54 mg/kg showed better effects than simvastatin at
10 mg/kg on reducing TCH level and similar effects on
TG, HDL and LDL.
Abbreviations
AEE: Aspirin eugenol ester; BW: Body weight; CMC-Na: Sodium
carboxymethyl cellulose; HDL: High density lipoprotein; HFD: High fat diet;
LDL: Low density lipoprotein; SRD: Standard rat diet; TCH: Total cholesterol;
TG: Triglycerides
Acknowledgements
The work was supported by the National Natural Science Foundation of
China (No.31402254) and the Natural Science Foundation for Youth of Gansu
Province (1506RJYA148).
Funding
The funders had no role in the design of the study and collection, analysis,
and interpretation of data and in writing the manuscript.
Availability of data and materials
All data generated or analyzed during the current study are available from
the corresponding author on reasonable request.
Authors’ contributions
Conceived and designed the experiments: NM JYL. Performed the
experiments: NM IM ZXL. Analyzed the data: NM YJY XWL IM. Contributed
reagents/materials/analysis tools: IM NM XWL XJK. Wrote the paper: NM YJY
JYL. All authors read and approved the final manuscript.
Competing interests




The study protocol was approved by the Institutional Animal Care and Use
Committee of Lanzhou Institute of Husbandry and Pharmaceutical Science of
the Chinese Academy of Agricultural Sciences. Animal welfare and
experimental procedures were performed strictly in accordance with the
Guidelines for the Care and Use of Laboratory Animals issued by the US
National Institutes of Health.
Received: 4 September 2016 Accepted: 10 November 2016
References
1. Xu C, Wang X, Wang S. Effect of soybean protein and high calcium intake
on the concentration of serum lipids in hypercholesterolemic rats.
Zhonghua Yu Fang Yi Xue Za Zhi. 2001;35(5):318–21.
2. Graham JM, Higgins JA, Taylor T, Gillott T, Wilkinson J, Ford TC, et al. A
novel method for the rapid separation of human plasma lipoproteins using
self-generating gradients of Iodixanol. Biochem Soc Trans. 1996;24(2):170S.
3. Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer
M, et al. Global, regional, and national comparative risk assessment of 79
behavioural, environmental and occupational, and metabolic risks or
clusters of risks in 188 countries, 1990–2013: a systematic analysis for the
Global Burden of Disease Study 2013. Lancet. 2015;386(10010):2287–323.
4. Lin HL, Yen HW, Hsieh SL, An LM, Shen KP. Low-dose aspirin ameliorated
hyperlipidemia, adhesion molecule, and chemokine production induced by
high-fat diet in Sprague–Dawley rats. Drug Dev Res. 2014;75(2):97–106.
5. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal
of obesity- and diet-induced insulin resistance with salicylates or targeted
disruption of Ikkbeta. Science. 2001;293(5535):1673–7.
6. Suanarunsawat T, Boonnak T, Na AW, Thirawarapan S. Anti-hyperlipidemic
and cardioprotective effects of Ocimum sanctum L. fixed oil in rats fed a
high fat diet. J Basic Clin Physiol Pharmacol. 2010;21(4):387–400.
7. Suanarunsawat T, Ayutthaya WD, Songsak T, Thirawarapan S,
Poungshompoo S. Lipid-lowering and antioxidative activities of aqueous
extracts of Ocimum sanctum L. leaves in rats fed with a high-cholesterol
diet. Oxid Med Cell Longev. 2011;2011:962025.
8. Sarkar A, Lavania SC, Pandey DN, Pant MC. Changes in the blood lipid
profile after administration of Ocimum sanctum (Tulsi) leaves in the normal
albino rabbits. Indian J Physiol Pharmacol. 1994;38(4):311–2.
9. Li J, Yu Y, Wang Q, Zhang J, Yang Y, Li B, et al. Synthesis of aspirin eugenol
ester and its biological activity. Med Chem Res. 2012;21(7):995–9.
10. Shen Y, Liu X, Yang Y, Li J, Ma N, Li B. In vivo and in vitro metabolism of
aspirin eugenol ester in dog by liquid chromatography tandem mass
spectrometry. Biomed Chromatogr. 2015;29(1):129–37.
11. Li J, Yu Y, Yang Y, Liu X, Zhang J, Li B, et al. A 15-day oral dose toxicity
study of aspirin eugenol ester in Wistar rats. Food Chem Toxicol.
2012;50(6):1980–5.
12. Li J, Kong X, Li X, Yang Y, Zhang J. Genotoxic evaluation of aspirin eugenol
ester using the Ames test and the mouse bone marrow micronucleus assay.
Food Chem Toxicol. 2013;62:805–9.
13. Ma N, Liu XW, Yang YJ, Li JY, Mohamed I, Liu GR, et al. Preventive Effect of
Aspirin Eugenol Ester on Thrombosis in kappa-Carrageenan-Induced Rat Tail
Thrombosis Model. PLoS One. 2015;10(7):e133125.
14. Thomas HD, Maynard C, Wagner GS, Eisenstein EL. Results from a practice-
based lipid clinic model in achieving low density lipoprotein cholesterol
goals. N C Med J. 2003;64(6):263–6.
15. Karam I, Ma N, Liu XW, Li SH, Kong XJ, Li JY, et al. Regulation effect of
Aspirin Eugenol Ester on blood lipids in Wistar rats with hyperlipidemia.
BMC Vet Res. 2015;11:217.
16. Wang Z, Li P, Wang C, Jiang Q, Zhang L, Cao Y, et al. Protective effects of
Arctium lappa L. root extracts (AREs) on high fat diet induced quail
atherosclerosis. BMC Complement Altern Med. 2016;16(1):6.
17. Rosini TC, Silva AS, Moraes C. Diet-induced obesity: rodent model for the
study of obesity-related disorders. Rev Assoc Med Bras. 2012;58(3):383–7.
18. Xu S, Liu Z, Liu P. HDL cholesterol in cardiovascular diseases: The good, the
bad, and the ugly? Int J Cardiol. 2013;168(4):3157–9.
19. Bakillah A, Hussain MM. Mice subjected to aP2-Cre mediated ablation of
microsomal triglyceride transfer protein are resistant to high fat diet
induced obesity. Nutr Metab (Lond). 2016;13:1.
20. Jugdaohsingh R, Kessler K, Messner B, Stoiber M, Pedro LD, Schima H, et al.
Dietary Silicon Deficiency Does Not Exacerbate Diet-Induced Fatty Lesions
in Female ApoE Knockout Mice. J Nutr. 2015;145(7):1498–506.
21. Hao L, Lu X, Sun M, Li K, Shen L, Wu T. Protective effects of L-arabinose in
high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. Food
Nutr Res. 2015;59:28886.
22. Jin Z, Li W, Cao H, Zhang X, Chen G, Wu H, et al. Antimicrobial activity and
cytotoxicity of N-2-HACC and characterization of nanoparticles with N-2-
HACC and CMC as a vaccine carrier. Chem Eng J. 2013;221:331–41.
23. Abdel-Galil A, Ali HE, Atta A, Balboul MR. Influence of nanostructured TiO2
additives on some physical characteristics of carboxymethyl cellulose (CMC).
J Radiat ResAppl Sci. 2014;7(1):36–43.
Karam et al. Lipids in Health and Disease  (2016) 15:196 Page 5 of 5
